Lifeway Foods Inc Dossier
|
SectorConsumer Staples IndustryPackaged Foods & Meats Beta (adjusted)0.64 Intrinsic Value $16.85median of 6 methods · middle span $13-$23based on filings through 30 Jun 2026 Market Price $21.10Price as of 1 Oct 2026 OvervaluedIntrinsic value is 20% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $318.8M Enterprise Value $311.7M Shares Outstanding 15.5M diluted Moat Rating Wide Next Earnings Date12 Nov 2026 Last ex-dividend29 May 2013 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Lifeway Foods, Inc. (LWAY) represents a compelling growth story in the functional dairy and gut-health sector, commanding over 90% of the U.S. kefir market. The company has demonstrated exceptional operational momentum, posting its 26th consecutive quarter of year-over-year growth in Q1 2026 with net sales surging 36.7% to $63.01 million. Crucially, the long-standing corporate governance overhang and hostile takeover friction with Danone have reached a definitive resolution. In May 2026, Danone initiated the complete divestment of its 22.7% stake via a secondary offering at $19.50 per share, allowing Lifeway to repurchase $5 million of its own shares and move forward with a clean slate. With a major multi-million dollar capacity expansion in Waukesha, Wisconsin on track to double production capacity by Q3 2026, and the launch of high-potential innovations like Muscle Mates, Lifeway is uniquely positioned to capitalize on secular tailwinds in probiotics, protein-rich diets, and GLP-1 weight-loss companion nutrition. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$34.00 Mean target$34.50 High · most bullish analyst$35.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario A sharp rise in raw milk and transportation costs compresses gross margins. The final stages of the Waukesha facility expansion face operational delays or cost overruns, limiting near-term volume growth. Consumer spending on premium functional dairy products softens due to macroeconomic pressures, or competition in the probiotic space intensifies as Danone scales its own internal gut-health brands (such as Activia) post-exit. Top-line growth slows to the single digits, and administrative expenses remain elevated. Base CaseCentral scenario Lifeway successfully completes its Waukesha facility expansion by Q3 2026, doubling production capacity to meet robust consumer demand. The company maintains a double-digit top-line growth trajectory, fueled by expanded distribution in major retailers (Target, Whole Foods, Walmart) and strong adoption of its high-protein Muscle Mates line. Operating margins stabilize or expand slightly as raw milk prices remain favorable and legal/administrative expenses decline following the Danone separation. The company remains on track to achieve its long-term target of $45 million to $50 million in Adjusted EBITDA by FY 2027. Bull CaseUpside scenario Lifeway Foods (LWAY) presents a strong bull case driven by robust organic volume growth, with Q1 2026 net sales surging 37% year-over-year to $63 million and gross margins expanding to 27.5%. The company is capitalizing on powerful secular tailwinds in gut health, probiotic-rich functional foods, and the rapid expansion of the GLP-1 weight-loss medication market, where patients seek high-protein, nutrient-dense dairy options to manage nutritional needs and side effects. To meet this accelerating demand, Lifeway is executing a $45 million, four-phase capacity expansion at its Waukesha, Wisconsin facility designed to double its overall production capacity by the third quarter of 2026. Furthermore, the resolution of its long-running corporate battle with Danone—culminating in Danone's complete exit via a secondary offering in May 2026—removes a major governance distraction, allowing Lifeway to execute its independent growth strategy with a clean, debt-free balance sheet. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |